Clinical Trial

A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated May 9, 2023 (before its estimated January 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The main purpose of this study is to evaluate the efficacy and safety of GB491 combined with Letrozole versus placebo combined with Letrozole in the treatment of HR+/HER2- locally advanced or metastatic breast cancer without prior systemic antitumor therapy
Trial Details
NCT Number NCT05851014
Lead Sponsor Genor Biopharma Co., Ltd.
Conditions Breast Cancer
Enrollment 350 participants
Start Date 2022-01-14
Primary Completion 2026-01-30 (estimated)
Study Completion 2027-01-30 (estimated)
Updated on ClinicalTrials.gov 2023-05-09